The influence of reproductive phase on lipopolysaccharide stimulation of prostacyclin production and cyclooxygenase-2 protein concentrations in reproductive and systemic arteries of the sheep.
Cyclooxygenase, the enzyme that converts arachidonate to prostaglandins, plays a regulatory role in vasodilation under normal and pathological conditions. Studies were conducted to determine the effects of reproductive phase and lipopolysaccharide (LPS) on production of PGI2 and amounts of cyclooxygenase protein in uterine, mammary, mesenteric, and renal arteries. Arteries were collected from ewes during the follicular (Day 0 = estrus) or luteal (Day 10) phase of the estrous cycle and were cultured in the presence of LPS. After 24 h, media were collected and analyzed for 6-keto-PGF1alpha, the stable metabolite of PGI2. In addition, arteries were collected and homogenized and the relative concentration of cyclooxygenase was determined via Western analysis. Lipopolysaccharide stimulated PGI2 production in all four-artery types from both follicular and luteal phase ewes (p < 0.001). Upon LPS stimulation, uterine and mammary arteries produced more PGI2 compared to mesenteric and renal arteries (p = 0.04). The phase of estrous cycle did not affect PGI2 production by any of the artery populations exposed to LPS (p = 0.35). There was no cyclooxygenase-2 in untreated uterine and mammary arteries and no cyclooxygenase-2 was detected in untreated or LPS-treated mesenteric and renal arteries. In contrast, LPS-treated uterine and mammary arteries from luteal phase ewes had higher (p = 0.064) cyclooxygenase-2 concentrations than those from follicular phase ewes. These results suggest that the hormone conditions of the follicular (high estrogen) and luteal (high progesterone) phases of the ovarian cycle play a role in regulating uterine and mammary artery but not mesenteric and renal artery response to LPS.
Janowiak
M A
MA
Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan 84322, USA.
Holyoak
G R
GR
Vagnoni
K E
KE
D015121:6-Ketoprostaglandin F1 alpha / Q000032:analysis; D000818:Animals; D001158:Arteries / Q000737:chemistry / Q000187:drug effects / Q000201:enzymology; D046508:Culture Techniques; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D011464:Epoprostenol / Q000032:analysis / Q000096:biosynthesis*; D004971:Estrus / Q000502:physiology*; D005260:Female; D005498:Follicular Phase; D007527:Isoenzymes / Q000032:analysis / Q000187:drug effects*; D008070:Lipopolysaccharides / Q000378:metabolism / Q000494:pharmacology*; D008183:Luteal Phase; D008323:Mammary Arteries / Q000737:chemistry / Q000187:drug effects; D008638:Mesenteric Arteries / Q000737:chemistry / Q000187:drug effects; D011451:Prostaglandin-Endoperoxide Synthases / Q000032:analysis / Q000187:drug effects*; D011460:Prostaglandins F / Q000032:analysis; D012077:Renal Artery / Q000737:chemistry / Q000187:drug effects; D012756:Sheep / Q000378:metabolism* / Q000502:physiology; D014599:Uterus / Q000098:blood supply
D007527:Isoenzymes; D008070:Lipopolysaccharides; D011460:Prostaglandins F; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases